Dr. Anil Philip Kunnath

Dr. Dr. Anil Philip Kunnath


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in British Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
DKDr. Anil Philip Kunnath
Dr. Anil Philip Kunnath
MSMohamed Suodha Suoodh
Mohamed Suodha Suoodh
DCDinesh Kumar Chellappan
Dinesh Kumar Chellappan
JCJestin Chellian
Jestin Chellian
KPKishneth Palaniveloo
Kishneth Palaniveloo
The global issue of antimicrobial resistance poses significant challenges to public health. The World Health Organization (WHO) has highlighted it as a major global health threat, causing an estimated 700,000 deaths worldwide. Understanding the multifaceted nature of antibiotic resistance is crucial for developing effective strategies. Several physiological and biochemical mechanisms are involved in the development of antibiotic resistance. Bacterial cells may escape the bactericidal actions of the drugs by entering a physiologically dormant state known as bacterial persistence. Recent findings in this field suggest that bacterial persistence can be one of the main sources of chronic infections. The antibiotic tolerance developed by the persister cells could tolerate high levels of antibiotics and may give rise to persister offspring. These persister offspring could be attributed to antibiotic resistance mechanisms, especially in chronic infections. This review attempts to shed light on persister-induced antibiotic resistance and the current therapeutic strategies.

18 September 2020 in Foods
Verified
Journal Article
Open access
PDF file
AAAbdulQudus Aroyehun
AbdulQudus Aroyehun
SRShariza Abdul Razak
Shariza Abdul Razak
KPKishneth Palaniveloo
Kishneth Palaniveloo
TNThilahgavani Nagappan
Thilahgavani Nagappan
NRNur Suraiza Nabila Rahmah
Nur Suraiza Nabila Rahmah
DKDr. Anil Philip Kunnath
Dr. Anil Philip Kunnath
Caulerpa racemosa (Forsskal) J. Agardh is a green seaweed used as food and folk medicine since ancient times in the Indo-Pacific region, particularly in southeast Asia. In this study, the proximate nutrient composition, phytochemical, anti-oxidant and anti-diabetic properties of sea grape C. racemosa collected from culture fishponds in Johor, Malaysia were analysed. The contents (dry weight basis) of carbohydrate, crude protein, crude lipids, ash and caloric value obtained were 33.42 ± 1.34%, 20.27 ± 0.14%, 4.20 ± 0.32%, 28.25 ± 0.27% and 2544.67 ± 7.04 cal g−1, respectively. The amino acid score (AAs) and biological protein value (213.43 mg g−1) indicated that C. racemosa presented a better protein quality. The most abundant fatty acids were C16:0 (palmitic acid: 63.27%), followed by C18:1 (oleic acid: 5.80%), and C18:2 ῳ6 (linoleic acid: 5.33%). The analysis of the ash content indicated that essential minerals and trace elements, such as Ca, Fe, and Mn, were present in the seaweed. The total phenolic content (TPC) and total flavonoid content (TFC) observed in the ethyl acetate extract were 17.88 ± 0.78 mg GAE g−1 and 59.43 ± 2.45 mg QE g−1, respectively. The ethyl acetate extract of C. racemosa demonstrated notable anti-diabetic activity in diabetic induced rats. The low (100 mg kg−1) and high (200 mg kg−1) doses of cultivated C. racemosa extract exhibited a significant decrease (p < 0.05) in blood glucose levels while preventing weight loss, reducing plasma AST, ALT levels as a sign of hepatoprotective effect and recording albumin levels similar to positive control in diabetic induced rats. The results support the usefulness of cultivated C. racemosa as a potential functional food.

23 March 2019 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
GXGriselda Lim Loo Xin
Griselda Lim Loo Xin
YKYap Pui Khee
Yap Pui Khee
TYTan Yoke Ying
Tan Yoke Ying
JCJestin Chellian
Jestin Chellian
GGGaurav Gupta
Gaurav Gupta
DCDinesh Kumar Chellappan
Dinesh Kumar Chellappan

1 July 2023 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
DCDinesh Kumar Chellappan
Dinesh Kumar Chellappan
JCJestin Chellian
Jestin Chellian
NRNur Suraiza Nabila Rahmah
Nur Suraiza Nabila Rahmah
WGWee Jin Gan
Wee Jin Gan
PBPriyanka Banerjee
Priyanka Banerjee
KPKishneth Palaniveloo
Kishneth Palaniveloo
Diabetes mellitus (DM) is a chronic metabolic disorder recognized as a major health problem globally. A defective insulin activity contributes to the prevalence and expansion of DM. Treatment of DM is often hampered by limited options of conventional therapies and adverse effects associated with existing procedures. This has led to a spike in the exploration for potential therapeutic agents from various natural resources for clinical applications. The marine environment is a huge store of unexplored diversity of chemicals produced by a multitude of organisms. To date, marine microorganisms, microalgae, macroalgae, corals, sponges, and fishes have been evaluated for their anti-diabetic properties. The structural diversity of bioactive metabolites discovered has shown promising hypoglycaemic potential through in vitro and in vivo screenings via various mechanisms of action, such as PTP1B, α-glucosidase, α-amylase, β-glucosidase, and aldose reductase inhibition as well as PPAR alpha/gamma dual agonists activities. On the other hand, hypoglycaemic effect is also shown to be exerted through the balance of antioxidants and free radicals. This review highlights marine-derived chemicals with hypoglycaemic effects and their respective mechanisms of action in the management of DM in humans.

20 August 2021 in Foods
Verified
Journal Article
Open access
PDF file
KPKishneth Palaniveloo
Kishneth Palaniveloo
LYLiaw Yee-Yinn
Liaw Yee-Yinn
LJLeong Jia-Qi
Leong Jia-Qi
ACAlvin Chelliah
Alvin Chelliah
SSSze-Looi Song
Sze-Looi Song
DKDr. Anil Philip Kunnath
Dr. Anil Philip Kunnath
Seaweeds are an important ingredient of functional foods recommended for daily food, due to their unique compositions and nutritional value. Padina tetrastromatica is a brown edible seaweed that is commonly found along the coastal regions of Peninsular Malaysia and consumed as food by some coastal communities. This study investigates the nutritional and antihyperglycaemic potential of P. tetrastromatica extracts, which is generally accepted as an important functional food. In our methodology, we induced diabetes intraperitoneally in experimental animals with a dose of 65 mg kg−1 body weight of streptozotocin. Oral treatment with 200 and 400 mg kg−1 of P. tetrastromatica ethanolic and ethyl acetate extracts were initiated, respectively, to experimental rats once daily for 18 days. Metformin was used as the positive control. Biochemical estimations and histopathological analysis were included in this study. Treatment with P. tetrastromatica extracts significantly lowered the plasma glucose levels in Streptozotocin-induced diabetic rats. In addition, P. tetrastromatica extract treatment also showed a significant reduction in serum alanine transaminase levels. However, no significant changes were observed in serum aspartate transaminase levels. The ethyl acetate extract of P. tetrastromatica at 400 mg kg−1 dose shows some nephroprotective effect, which is observed from the significant increase in the plasma albumin levels. Histopathological evaluation revealed no marked morphological changes in tissues of the isolated organs of the ethyl acetate extract-treated group, revealing the safe nature of P. tetrastromatica.

16 December 2025 in Bioscience Reports
Verified
Journal Article
Open access
BKBrenda Wen Keng-Lim
Brenda Wen Keng-Lim
KCKelvin Yee Chen-Ng
Kelvin Yee Chen-Ng
JYJia Yee-Lee
Jia Yee-Lee
Ching-Hsein ChenChing-Hsein Chen
Ching-Hsein Chen
WLWan Ling-Chang
Wan Ling-Chang
CMChye Moi
Chye Moi
Background: Prediabetes in individuals with obesity is a high-risk state for progression to type 2 diabetes mellitus (T2DM). Circulating microRNAs (miRNAs) have emerged as promising minimally invasive biomarkers for early detection. However, their diagnostic performance and consistency across studies remain unclear. Objectives: To evaluate circulating miRNAs as potential biomarkers for prediabetes in obese populations. Methods: A systematic search of PubMed, MEDLINE, Scopus, and EBSCOhost was conducted (September 2012–September 2025) without language restrictions. Eligible studies included observational, clinical, and translational research assessing circulating miRNAs in plasma, serum, whole blood, or exosomes using qRT-PCR, ddPCR, microarray, or next-generation sequencing. Two reviewers independently screened studies and extracted data using a piloted form. Extracted information was synthesized qualitatively; diagnostic performance measures and reported miRNAs were tabulated. Results: Nine circulating microRNAs (miR-27, miR-30a, miR-34a, miR-93, miR-122, miR-126, miR-146a, miR-192, and miR-193b) were consistently dysregulated in obese individuals with prediabetes across thirteen included human studies. These miRNAs were linked to key pathogenic mechanisms including chronic inflammation, insulin resistance, β-cell dysfunction, and altered adipokine signaling. Notably, inflammation-associated miRNAs (miR-27, miR-34a, miR-146a) reflected the transition from metabolically healthy to unhealthy obesity, while β-cell–related miRNAs (miR-30a, miR-126) indicated early impairment of insulin secretion. Among detection platforms, qRT-PCR remained the most sensitive and specific method for miRNA quantification, whereas microarray and next-generation sequencing provided broader profiling capability but with higher cost and complexity. Conclusions: Circulating miRNAs demonstrate promise as diagnostic biomarkers for prediabetes in obesity. However, these findings are limited by methodological variability. Thus, large-scale and standardized studies are required to validate their clinical utility.